Your browser doesn't support javascript.
loading
Retraction notice to "MiR-1290 promotes cancer progression by targeting nuclear factor I/X(NFIX) in esophageal squamous cell carcinoma (ESCC)" [Biomed. Pharmacother. 76 (2015) 82-93].
Mao, Yu; Liu, Jia; Zhang, Dakai; Li, Baosheng.
Affiliation
  • Mao Y; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, China.
  • Liu J; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, China; School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan, China.
  • Zhang D; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, China; School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan, China.
  • Li B; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, China. Electronic address: baoshli1963@163.com.
Biomed Pharmacother ; 171: 116189, 2024 02.
Article in En | MEDLINE | ID: mdl-38296731
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Biomed Pharmacother Year: 2024 Document type: Article Affiliation country: China Country of publication: France
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Biomed Pharmacother Year: 2024 Document type: Article Affiliation country: China Country of publication: France